| Affiliation: | (1) Department of Human and Molecular Genetics, Virginia Commonwealth University, Richmond, VA 23298, USA;(2) VCU Institute of Molecular Medicine, Richmond, VA 23298, USA;(3) VCU Massey Cancer Center, Richmond, VA 23298, USA;(4) Department of Microbiology and Immunology, Virginia Commonwealth University, Richmond, VA 23298, USA;(5) Department of Immunology, Roswell Park Cancer Institute, Buffalo, NY 14263, USA; |
| Abstract: | In this study, we report a novel treatment strategy that could potentially be used to improve efficacy of adoptive cell therapy for patients with prostate cancer. We show that female C57BL/6 mice are able to effectively reject two syngeneic prostate tumors (TRAMP-C2 and RM1) in a T cell-dependent manner. The protective antitumor immunity appears to primarily involve T cell responses reactive against general prostate tumor/tissue antigens, rather than simply to male-specific H-Y antigen. For the first time we show that adoptive transfer of lymphocytes from TRAMP-C2-primed or naïve female mice effectively control prostate tumor growth in male mice, when combined with host pre-conditioning (i.e., non-myeloablative lymphodepletion) and IL-2 administration. No pathological autoimmune response was observed in the treated tumor-bearing male mice. Our studies provide new insights regarding the immune-mediated recognition of male-specific tissue, such as the prostate, and may offer new immunotherapy treatment strategies for advanced prostate cancer. |
